ѻý

Alzheimer's Trials Investigated; Chronic Pain Predicted; Dementia Drugs and AMD

<ѻý class="mpt-content-deck">— News and commentary from the world of neurology and neuroscience
MedpageToday
Neuro Break over a computer rendering of neurons.

A New York Times investigation reported that in early studies of lecanemab (Leqembi) and donanemab (Kisunla), participants were to know whether they carried APOE4, a genetic variant with higher risks of brain edema and bleeding after anti-amyloid treatment.

Most older adults with of cognitive impairment who received primary care at a federally qualified health center actually had mild cognitive impairment or dementia. (JAMA Network Open)

The overall for older adults with Alzheimer's disease was 36.1 visits per 1,000 adults in 2020-2022; for Black Alzheimer's patients, it was 71.3 visits per 1,000. (NCHS Data Brief)

Poor cardiovascular health in midlife was associated with a of developing a composite outcome of diseases tied to poor brain health. (Neurology)

Hippocampal functional connectivity after whiplash injury predicted to chronic pain. (Nature Mental Health)

Two commonly prescribed dementia drugs -- memantine and donepezil -- were not associated with a reduced risk of developing (AMD), contrary to earlier findings. (JAMA Network Open)

Researchers identified in a large neuropathology genome-wide association study. (Nature Genetics)

Choroid plexus volume was greater in participants with than in healthy controls. (Neurology: Neuroimmunology and Inflammation)

Neurologists in Australia called for the country's chemical regulator to due to its links with Parkinson's disease. (ABC News)

Athletes who recalled that they had after at least one collision associated it with a self-reported concussion. (Diagnostics)

  • Judy George covers neurology and neuroscience news for ѻý, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.